Full-Time

Clinical Trial Nurse/Medtech RN

Confirmed live in the last 24 hours

IQVIA

IQVIA

10,001+ employees

Analytics and research for life sciences

Compensation Overview

$55 - $70/hr

+ Incentive Plans + Bonuses

Junior, Mid

No H1B Sponsorship

Los Angeles, CA, USA

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a IQVIA referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • At least 2 years' experience working in a clinical research setting required or High School Diploma and 3 years’ relevant work experience in clinical research
  • Applicable certifications and licenses as required by company, country, state, and/or other regulatory bodies. RN license in California
  • Working knowledge of clinical trials
  • Working knowledge of the principles of Good Clinical Practices (GCP)
  • In-depth knowledge of protocol and study-specific operating procedures, consent forms, and study schedules
  • Skill in carrying out required clinical procedures
  • Working knowledge of medical terminology
  • Ability to pay close attention to detail
  • Ability to establish and maintain effective working relationships with coworkers, managers, patients, physicians, and clients.
Responsibilities
  • Perform a variety of complex clinical procedures on subjects
  • Coordinate and support clinical research studies conducted by a supervising principal investigator
  • Update and maintain skills, training, and knowledge of current best nursing practices and topics related to clinical research
  • Safeguard the well-being of the subjects and ensure and maintain high standards
  • Maintain a safe environment in accordance with Health and Safety policies
  • Act as a volunteer advocate
  • Address volunteer and visitor concerns proactively and take remedial action as required
  • Assist staff, both registered and unregistered, in clinical coordinator practices and the delivery of care to the volunteer
  • Report any deviation from normal practice to senior staff
  • Reviewing the study protocol, case report form (CRF), other study documents, and electronic data capture systems
  • Participating in project meetings with the project team as needed
  • Performing clinical set-up and preparation for the study including labeling specimen collection tubes and containers, setting up equipment and documents
  • Planning logistical activity for procedures as per protocol
  • Generating volunteer instructions
  • Identifying and obtaining required supplies and equipment
  • Preparing and delivering study-specific training materials, documents, and records
  • Troubleshooting study issues
  • Participating in huddles to ensure daily tasks assigned to team members are executed to the expected standards
  • Assisting with data quality checking and query resolution to ensure that data collected on study volunteers adhere to study protocol and ensuring quality control for content accuracy and completeness
  • Recruiting and screening volunteers for inclusion in the study based on pre-determined criteria
  • Orienting volunteers to the study and the site including the purpose of the study, procedures, and practical issues such as timelines for visits
  • Responsible for the correct administration and custody of study drug according to site standard operating procedures
  • Collecting, recording, and reporting clinical data and findings appropriately in case report forms (CRFs)
  • Collaborating closely with the study investigator, informing on relevant adverse events and serious adverse events according to procedures outlined in the protocol
  • Cooperating with the study monitor and reserving sufficient time for questions during monitoring
  • Following ICH GCP guidelines with regards to all study and patient activities.

IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main product, IQVIA Connected Intelligence™, utilizes big data and technology to offer insights that help clients speed up the development and marketing of new medical treatments. This system connects various healthcare data points to provide a comprehensive view of patient needs and treatment effectiveness. Unlike many competitors, IQVIA places a strong emphasis on patient privacy, using advanced technologies to protect individual data. The company's goal is to enhance healthcare outcomes by supporting biotech, pharmaceutical, and medical device companies, as well as researchers and government agencies, in their efforts to understand diseases and improve treatment options.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • IQVIA's Med-R1 8B LLM enhances clinical data interpretation for healthcare professionals.
  • Recognition in IDC MarketScape boosts IQVIA's credibility in decentralized clinical trials.
  • Site Lab Navigator streamlines lab workflows, transforming clinical trial processes.

What critics are saying

  • CAR T-cell therapy access disparities may affect IQVIA's reputation.
  • Competition in AI models could impact Med-R1 8B's market share.
  • Existing lab automation solutions challenge Site Lab Navigator's adoption.

What makes IQVIA unique

  • IQVIA's Connected Intelligence™ offers rapid insights for healthcare innovation.
  • The company excels in protecting patient privacy with advanced technologies.
  • IQVIA's global presence spans over 100 countries with 86,000 employees.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Company News

PharmiWeb
Apr 24th, 2025
New Iqvia Institute Report Warns Of Access Disparities For Car T-Cell Therapy Across Europe

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%

Stock Titan
Apr 16th, 2025
Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer

LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments.

BioPharmaTrend
Apr 7th, 2025
IQVIA Introduces a Compact Medical Reasoning LLM Outscoring Larger Models

IQVIA has launched Med-R1 8B, a medical reasoning large language model (LLM) designed to assist healthcare professionals in interpreting complex clinical data and scientific literature.

PR Newswire
Mar 26th, 2025
'Business Of Life Sciences And Healthcare For Leaders' Forthcoming From Umd Smith Executive Education

COLLEGE PARK, Md., March 26, 2025 /PRNewswire/ -- Registration is open for "Business of Life Sciences and Healthcare for Leaders" (B-LSHC) — an immersive five-day program focused on leadership development and honing critical-thinking and problem-solving skills in medical product development presented by Smith Executive Education at the University of Maryland's Robert H. Smith School of Business.The in-person program takes place June 23-27, 2025, at Van Munching Hall on UMD's College Park campus and is designed for mid-to-advanced career professionals in the LSHC ecosystem including pharmaceutical, biotech and medical device industries; health policy; patient advocacy; regulators; investors; and leaders across medical and regulatory fields.Program sessions will begin at 8:30 a.m. each day "and end with a luminary keynote speaker who will inspire and challenge participants to think outside the box toward the goals of creating innovative solutions for some of our most challenging problems in the LSHC ecosystem," says Wendy Sanhai, PhD, professor of the practice in management and organization for the Smith School and one of the workshop's organizers.Participants will learn from world-renowned faculty, regulatory experts and industry leaders on how to make informed decisions at crucial stages of medical product (drugs, biologics and medical devices) development – from R&D and regulatory submission to commercial launch and reimbursement. And, through expert-led sessions, dynamic capstone project discussions and case-study analysis, participants will sharpen their problem-solving and critical-thinking skills as they expand their professional network.Instructors, in addition to Sanhai, will include UMD and Smith faculty experts Balaji Padmanabhan, director of Smith's Center for Artificial Intelligence in Business; management and organization professors Jennifer Carson Marr, Oliver Schlake and Subra Tangirala; marketing professor Judy Frels; School of Public Health Dean Boris Lushniak; and School of Pharmacy Professor Joga Gobburu.The UMD experts will be joined by leading industry experts including former CEO of Scorpion Therapeutics Axel Hoos, IntoValue CEO Marion Couch, Deloitte Principals Juergen Klenk, Candy Lurken and Mathias Cousin; Euclidean Life Science Advisors President Kenneth Moch; Licensing IP negotiator Steve Ferguson; leaders from IQVIA and former FDA leaders.Participants will:Sharpen problem-solving, leadership and critical-thinking skillsCultivate holistic thinking and multidisciplinary approaches for real-world problems in the LSHC ecosystemBuild upon lessons learned and best practices from regulatory experts, industry luminaries and academic leadersExpand their professional networkIdentify major milestones, potential challenges, risks and mitigation strategies across medical product development pathways in R&D, regulatory submission, product launch and commercializationExecute critical steps in license negotiations and technology transfer processesParticipants should have at least a bachelor's degree and five years of working experience in any LSHC field.Scholarships are available, including for nonprofits, government professionals and veterans. Discounts are available for organizations with multiple participants. Information sessions via Zoom are set for 1-2 p.m

HR Tech Wire
Mar 10th, 2025
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the "Leaders" category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment.